Related Experiment Videos
Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders
1Dipartimento di Ematologia, Centro Emofilia e Trombosi, Ospedale San Bortolo, Vicenza, Italia. castaman@hemato.ven.it
Insights
Rare inherited coagulation disorders (RICD) involve low-prevalence clotting factor deficiencies. Treatment with plasma-derived concentrates improves quality of life and reduces bleeding risks for affected individuals.
Area of Science:
- Hematology
- Genetics
- Rare Diseases
Background:
- Rare inherited coagulation disorders (RICD) are characterized by low-prevalence clotting factor deficiencies.
- Severe cases can lead to significant bleeding after procedures or spontaneously, similar to hemophilia but with unique complications like gynecological bleeding.
Purpose of the Study:
- To review the current understanding and management of rare inherited coagulation disorders.
- To highlight the impact of available treatments on patient outcomes and quality of life.
Main Methods:
- Literature review of rare inherited coagulation disorders.
- Analysis of treatment efficacy with plasma-derived concentrates.
Main Results:
- Plasma-derived concentrates (excluding factor V) are available and effective for managing RICD.
- These treatments have made surgery and prophylaxis more feasible, reducing life-threatening bleeding episodes.
Conclusions:
- Virally-inactivated plasma-derived concentrates significantly improve the quality of life for patients with RICD.
- Future goals include expanding access to these essential treatments, particularly in developing countries.
Abstract:
Rare inherited coagulation disorders (RICD) represent a group of inherited deficiencies of clotting factors characterized by a low prevalence in the general population (usually around 1:1,000,000 inhabitants) and, in severe cases (homozygous or compound heterozygotes), by the invariable occurrence of bleeding after invasive procedures if not adequately treated. Furthermore, spontaneous or post-traumatic severe bleeding may occur, as usually observed in patients with haemophilia, although less frequently. The clinical picture of patients with RICD may, however, be complicated by particular situations not encountered in haemophiliacs, such as gynaecological bleeding. The availability of virally-inactivated plasma-derived concentrates of the missing factors, apart from factor V, has rendered surgery and prophylaxis more feasible in these disorders, thus reducing the risk of life-threatening episodes and significantly improving the quality of life of affected patients. The goal for the future is to render this treatment accessible to all patients with these disorders, also to those living in developing countries.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...